Clinical Nanomedicine: A Solution to the Chemotherapy Conundrum in Pediatric Leukemia Therapy
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Clinical Nanomedicine: A Solution to the Chemotherapy Conundrum in Pediatric Leukemia Therapy
Authors
Keywords
-
Journal
CLINICAL PHARMACOLOGY & THERAPEUTICS
Volume 95, Issue 2, Pages 168-178
Publisher
Springer Nature
Online
2013-09-05
DOI
10.1038/clpt.2013.174
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Albumin-Bound Paclitaxel: The Benefit of This New Formulation in the Treatment of Various Cancers
- (2014) M. Montana et al. JOURNAL OF CHEMOTHERAPY
- Cyclodextrin-derived pH-responsive nanoparticles for delivery of paclitaxel
- (2013) Hongmei He et al. BIOMATERIALS
- First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies
- (2013) Glen J. Weiss et al. INVESTIGATIONAL NEW DRUGS
- Filomicelles in nanomedicine – from flexible, fragmentable, and ligand-targetable drug carrier designs to combination therapy for brain tumors
- (2013) Núria Sancho Oltra et al. Journal of Materials Chemistry B
- Targeted polymeric therapeutic nanoparticles: design, development and clinical translation
- (2012) Nazila Kamaly et al. CHEMICAL SOCIETY REVIEWS
- Pharmacokinetics of CPX-351; a nano-scale liposomal fixed molar ratio formulation of cytarabine:daunorubicin, in patients with advanced leukemia
- (2012) E.J. Feldman et al. LEUKEMIA RESEARCH
- Dexamethasone-Loaded Block Copolymer Nanoparticles Induce Leukemia Cell Death and Enhance Therapeutic Efficacy: A Novel Application in Pediatric Nanomedicine
- (2012) Vinu Krishnan et al. MOLECULAR PHARMACEUTICS
- Preclinical Development and Clinical Translation of a PSMA-Targeted Docetaxel Nanoparticle with a Differentiated Pharmacological Profile
- (2012) J. Hrkach et al. Science Translational Medicine
- Vascular and pharmacokinetic effects of EndoTAG-1 in patients with advanced cancer and liver metastasis
- (2011) U. Fasol et al. ANNALS OF ONCOLOGY
- A Phase I clinical study of cisplatin-incorporated polymeric micelles (NC-6004) in patients with solid tumours
- (2011) R Plummer et al. BRITISH JOURNAL OF CANCER
- Paclitaxel poliglumex for ovarian cancer
- (2011) Vijaya L Galic et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Phase II study of NK105, a paclitaxel-incorporating micellar nanoparticle, for previously treated advanced or recurrent gastric cancer
- (2011) Ken Kato et al. INVESTIGATIONAL NEW DRUGS
- Phase II study of a cremophor-free, polymeric micelle formulation of paclitaxel for patients with advanced urothelial cancer previously treated with gemcitabine and platinum
- (2011) Jae-Lyun Lee et al. INVESTIGATIONAL NEW DRUGS
- Anti-PEG IgM production by siRNA encapsulated in a PEGylated lipid nanocarrier is dependent on the sequence of the siRNA
- (2011) Tatsuaki Tagami et al. JOURNAL OF CONTROLLED RELEASE
- Differences in colloidal structure of PEGylated nanomaterials dictate the likelihood of accelerated blood clearance
- (2011) Lisa M. Kaminskas et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- Noninvasive, Transient and Selective Blood-Brain Barrier Opening in Non-Human Primates In Vivo
- (2011) Fabrice Marquet et al. PLoS One
- More Effective Nanomedicines through Particle Design
- (2011) Jin Wang et al. Small
- Overcoming in vivo barriers to targeted nanodelivery
- (2011) Adrian Chrastina et al. Wiley Interdisciplinary Reviews-Nanomedicine and Nanobiotechnology
- Tumor-Selective Delivery of Macromolecular Drugs via the EPR Effect: Background and Future Prospects
- (2010) Hiroshi Maeda BIOCONJUGATE CHEMISTRY
- Phase I Study of NK012, a Novel SN-38-Incorporating Micellar Nanoparticle, in Adult Patients with Solid Tumors
- (2010) T. Hamaguchi et al. CLINICAL CANCER RESEARCH
- A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction
- (2010) Juan W. Valle et al. INVESTIGATIONAL NEW DRUGS
- Phase I and Pharmacokinetic Study of Pegylated Liposomal CKD-602 in Patients with Advanced Malignancies
- (2009) W. C. Zamboni et al. CLINICAL CANCER RESEARCH
- Gastrosplenic Fistula From Hodgkin's Lymphoma
- (2009) Carolyn D. Seib et al. JOURNAL OF CLINICAL ONCOLOGY
- The First Targeted Delivery of siRNA in Humans via a Self-Assembling, Cyclodextrin Polymer-Based Nanoparticle: From Concept to Clinic
- (2009) Mark E. Davis MOLECULAR PHARMACEUTICS
- A phase II study of Campath-1H in children with relapsed or refractory acute lymphoblastic leukemia: A Children's Oncology Group report
- (2009) Anne L. Angiolillo et al. PEDIATRIC BLOOD & CANCER
- Effect of Surface Properties on NanoparticleâCell Interactions
- (2009) Ayush Verma et al. Small
- Update on developmental therapeutics for acute lymphoblastic leukemia
- (2009) Malcolm A. Smith Current Hematologic Malignancy Reports
- Twenty-five-year follow-up among survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study
- (2008) R. Mody et al. BLOOD
- Particle size-dependent triggering of accelerated blood clearance phenomenon
- (2008) Hiroyuki Koide et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
- Poly(ethylene glycol)s generate complement activation products in human serum through increased alternative pathway turnover and a MASP-2-dependent process
- (2008) I. Hamad et al. MOLECULAR IMMUNOLOGY
- Nanoparticle-mediated cellular response is size-dependent
- (2008) Wen Jiang et al. Nature Nanotechnology
- Nanoparticle therapeutics: an emerging treatment modality for cancer
- (2008) Mark E. Davis et al. NATURE REVIEWS DRUG DISCOVERY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started